AstraZeneca enters commercialisation agreement with Aspen for anaesthetic medicines portfolio
- Details
- Category: AstraZeneca
AstraZeneca today announced it has entered into a commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US. The agreement covers seven established medicines - Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest).
Bayer Science & Education Foundation launches new round of funding
- Details
- Category: Bayer
Applications for the Bayer Science & Education Foundation's international scholarship programs are now being accepted for this year's round. In the academic sector, ambitious students can apply for an Otto Bayer, Carl Duisberg, Jeff Schell, or Kurt Hansen scholarship if they are aiming to undertake a study project abroad or from foreign countries planning a project in Germany.
Boehringer Ingelheim and Harvard scientists establish a research alliance
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute's - Harvard Fibrosis Network to discover new ways of treating fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD) and nonalcoholic steatohepatitis (NASH).
Merck announces survey results exploring biopharma industry's evolving risk model
- Details
- Category: Merck Group
Merck, a leading science and technology company, today announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks associated with the changing biopharma landscape. The survey, sponsored by Merck, was conducted by the Economist Intelligence Unit (EIU), a leading resource for economic and business research, forecasting and analysis.
Pfizer presents promising data from next generation ALK/ROS1 inhibitor in advanced non-small cell lung cancer
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer's investigational, next-generation ALK/ROS1 tyrosine kinase inhibitor. The study showed clinical response in patients with ALK-positive or ROS1-positive advanced non-small cell lung cancer (NSCLC), including patients with brain metastases.
AstraZeneca licenses Zurampic to Grünenthal GmbH in Europe and Latin America
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America. Zurampic was approved by the European Medicines Agency (EMA) in February 2016, in combination with a xanthine oxidase inhibitor (XOI), for the adjunctive treatment of hyperuricemia (excess of uric acid in the blood) in adult patients with uncontrolled gout.
Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an easy-to-use, non-assert declaration for Viramune® (nevirapine).
More Pharma News ...
- Novartis highlights its strong foundation for long-term, sustainable growth
- Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing
- AstraZeneca highlights continued progress of oncology pipeline at ASCO 2016
- Merck and Pfizer to present Avelumab data in seven different cancers at ASCO annual meeting
- Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
- Johnson & Johnson announces collaboration with HP Inc. subsidiary to create personalized health care solutions with 3D printing technologies
- Novartis Foundation and partners launch innovative hypertension program in Vietnam